Neurocrine(NBIX) Prnewswire·2025-03-20 12:30Core Insights - Neurocrine Biosciences presented new data from the KINECT® 4 study showing that the majority of patients treated with INGREZZA® (valbenazine) capsules achieved remission of tardive dyskinesia (TD) [1][7] Study Findings - The KINECT 4 study involved 163 participants with moderate to severe TD and underlying psychiatric conditions, who received 48 weeks of treatment with INGREZZA [4] - A post-hoc analysis indicated that 59.2% of participants achieved remission, with 58.6% on the 40 mg dose and 59.5% on the 80 mg dose [8] - Significant improvements in the Abnormal Involuntary Movement Scale (AIMS) total scores were observed, with mean baseline scores decreasing from 12.4 (40 mg) and 15.1 (80 mg) to 2.1 and 2.5, respectively, at Week 48 [8] Treatment Efficacy - The findings suggest that INGREZZA is an effective long-term treatment option for TD, regardless of the underlying psychiatric condition [2][3] - Improvements in TD symptoms were consistent across different psychiatric diagnoses, with remission rates of 57.7% for schizophrenia or schizoaffective disorder and 62.5% for mood disorders [8] Safety and Tolerability - INGREZZA was generally well tolerated, with treatment emergent adverse events occurring in ≥ 5% of participants being urinary tract infection (8.5%) and headache (5.2%) [5] - Changes in psychiatric stability and vital signs were generally small and not clinically significant [5] About INGREZZA - INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treating adults with tardive dyskinesia and chorea associated with Huntington's disease [10][11] - The drug is unique in that it offers a therapeutic dose from day one without the need for titration [10]